title: Impact of hydrocortisone hemisuccinate use on outcome of severe scorpion-envenomed adult patients.
abstract: The aim of this study is to analyze if the infusion of hydrocortisone hemisuccinate improve outcome in severe scorpion-envenomated adult patients admitted to intensive care unit (ICU). Pairwise retrospective case-control study with 1:1 matching was designed. Patients were defined as cases when they received hydrocortisone hemisuccinate (as alone steroids) during hospitalization and as controls when they did not received any steroids. Patients were matched according to age, severity factors at admission represented by the presence of pulmonary edema and grades of severity of scorpion envenomation, and scorpion antivenom administration. Eighty-four patients were included as follows: 42 patients in the cases group and 42 patients in the control group. The mean age (±SD) was 40±21 years, ranging from 16 to 90 years. Moreover, 67 (80%) patients have a systemic inflammatory response syndrome on ICU admission. The comparison between cases group and control group showed that age is not significantly different. There were the same proportions of patients with pulmonary edema in 2 groups. Moreover, 23 (54%) patients in case group and 23 (54%) in the control group received scorpion antivenom (P>0.05). The mean temperature on admission was also not significantly different. The presence of systemic inflammatory response syndrome was again not significantly different between 2 groups. The comparison of outcome of the 2 groups showed that the use of mechanical ventilation and its duration, the ICU stay length, and ICU mortality was not significantly different between the 2 groups. Although our study has some limitations, it confirms that the use of hydrocortisone hemisuccinate in severe scorpion-envenomed patients did not improve their outcome.
authors.affiliation: Service de Réanimation médicale, CHU, Habib Bourguiba Route el Ain Km 1, Sfax, Tunisie.
authors.forename: Mabrouk
authors.initials: M
authors.lastname: Bahloul
authors.forename: Anis
authors.initials: A
authors.lastname: Chaari
authors.forename: Hassen
authors.initials: H
authors.lastname: Dammak
authors.forename: Najla
authors.initials: N
authors.lastname: Ben Algia
authors.forename: Fatma
authors.initials: F
authors.lastname: Medhioub
authors.forename: Chokri
authors.initials: C
authors.lastname: Ben Hamida
authors.forename: Hedi
authors.initials: H
authors.lastname: Chelly
authors.forename: Mounir
authors.initials: M
authors.lastname: Bouaziz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000997:Antivenins / Q000627:therapeutic use; D001733:Bites and Stings / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007362:Intensive Care Units; D007902:Length of Stay; D008875:Middle Aged; D011654:Pulmonary Edema / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D012604:Scorpion Venoms / Q000506:poisoning*; D012720:Severity of Illness Index; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000997:Antivenins; D012604:Scorpion Venoms; C007133:hydrocortisone hemisuccinate; D006854:Hydrocortisone